Rhythm Pharmaceuticals Inc (RYTM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Rhythm Pharmaceuticals Inc (RYTM) has a cash flow conversion efficiency ratio of -0.183x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-25.39 Million) by net assets ($139.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check Rhythm Pharmaceuticals Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Rhythm Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Rhythm Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See RYTM net assets for net asset value and shareholders' equity analysis.
Rhythm Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rhythm Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Coromandel International Limited
NSE:COROMANDEL
|
0.150x |
|
Marfrig Global Foods S.A.
SA:MRFG3
|
0.234x |
|
Changzhou Xingyu Automotive Lighting Systems Co Ltd
SHG:601799
|
0.053x |
|
QMMM Holdings Limited Ordinary Shares
NASDAQ:QMMM
|
-0.103x |
|
Hengdian Group DMEGC Magnetics Co Ltd
SHE:002056
|
0.120x |
|
Flagstar Financial, Inc.
NYSE:FLG
|
-0.016x |
|
Apar Industries Limited
NSE:APARINDS
|
0.035x |
|
Alkermes Plc
NASDAQ:ALKS
|
-0.095x |
Annual Cash Flow Conversion Efficiency for Rhythm Pharmaceuticals Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Rhythm Pharmaceuticals Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see RYTM market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $139.07 Million | $-115.67 Million | -0.832x | -20.19% |
| 2024-12-31 | $164.55 Million | $-113.88 Million | -0.692x | +13.71% |
| 2023-12-31 | $169.76 Million | $-136.16 Million | -0.802x | -22.21% |
| 2022-12-31 | $264.26 Million | $-173.43 Million | -0.656x | -27.72% |
| 2021-12-31 | $284.15 Million | $-146.00 Million | -0.514x | +29.85% |
| 2020-12-31 | $166.53 Million | $-121.98 Million | -0.732x | -67.69% |
| 2019-12-31 | $281.02 Million | $-122.75 Million | -0.437x | -73.34% |
| 2018-12-31 | $246.26 Million | $-62.06 Million | -0.252x | -23.85% |
| 2017-12-31 | $144.79 Million | $-29.46 Million | -0.203x | +93.61% |
| 2016-12-31 | $7.30 Million | $-23.22 Million | -3.182x | -1359.47% |
| 2015-12-31 | $32.00 Million | $-6.98 Million | -0.218x | -101.04% |
| 2014-12-31 | $-358.00K | $-7.51 Million | 20.972x | +6190.74% |
| 2013-12-31 | $-57.46 Million | $-19.16 Million | 0.333x | -32.16% |
| 2012-12-31 | $-36.28 Million | $-17.83 Million | 0.491x | -- |
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, … Read more